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We encapsulated vincristine into folic acid-conjugated PEGylated liposomes to improve the
anti-tumor efficacy on multidrug resistant cancers. It was observed that the drug delivery
system we constructed exhibited maximum cytotoxicity on KBv200 cells (multidrug
resistant variant) compared with any other formulations. The semi-quantitative analysis of
region of interest revealed that there was a great increase in area under curve (AUC) of a
near-infrared fluorescein in solid tumors due to folic acid-mediated accumulation. Folic
acid-conjugated PEGylated liposomes showed a significant tumor growth inhibiting effect
in vitro and in vivo. TUNEL assay revealed that folic acid-conjugated PEGylated liposomes
could induce cell apoptosis much more greatly than others. This study demonstrated that
it had potential application prospective for the treatment of multidrug resistant cancer.
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cially nanomedical strategies [2]. Nanoparticles have shown
the ability to target tumors based on their unique physical and
biological properties. To date, nanoparticles have been
investigated primarily to address P-gp and the observed
improved anticancer efficacy suggests that nanomedicinal
strategies provide a new opportunity to overcome MDR.
Therefore, development of nanocarriers for overcoming MDR
is indispensable to facilitate successful progress of chemo-
therapy. Many researchers co-encapsulated cytotoxic agents
with P-gp inhibitors together into nanoparticles to overcome
the efflux of P-gp, resulting in the enrichment of anti-tumor
drugs in tumors. However, it is widely recognized that the
clinical use of P-gp inhibitors, including verapamil (VRP),
quinidine, cyclosporine-A, PSC833, VX-710, etc., are limited by
unacceptable toxicity, unpredictable pharmacokinetic in-
teractions with the anticancer drug and interactions with
other transport proteins. Moreover, these inhibitors have poor
specificity on P-gp. P-gp is widely distributed in the intestine,
lung, kidney, liver, adrenal gland, bloodebrain barrier, and
placenta, and plays a vital role of the normal metabolism.
Therefore, it’s better to develop a new drug delivery system
(DDS) that doesn’t contain P-gp inhibitors but can achieve
a similar anti-tumor efficacy as the co-encapsulated DDS.
Clinically, overexpression of P-gp is not the only reason for
MDR. Cellular interaction, drug dissolution, cellular adhesion
and other reasons are confirmed to have close relationship
with MDR [3e5]. There, it is difficult to solve the MDR problem
focusing on any of the reasons, such as P-gp inhibition. Most
of the organisms (including human beings and bacteria) share
a set of MDR mechanism which is the same as the one of
tumor. This self-defensive system help all the beings to sur-
vive when met with toxic agents after billion years’ evolution
[6]. Nevertheless, even if they own the self-defensive system,
the MDR cells will also die when they are put into a micro-
environment where the drug concentration is as 10e100 fold
as the lethal dosage of sensitive cells [7e9]. This reveals that
self-defensive system will not work when the outer drug
concentration is high enough, no matter what kind of MDR
mechanism is responsible for its MDR. Once the extracellular
drug concentration exceed the threshold, all the MDR mech-
anism will not work anymore.
If we can construct a drug delivery system which will in-
crease the drug concentration in the targeted areas, inducing
the collapse of self-defensive system, these MDR cells will be
killed whether P-gp inhibitors are co-encapsulated or not.
Consequently, the growth of the tumor will cease and the pa-
tients’ lives will be prolonged. The present study was devised
with an objective of solving the above-mentioned obstacles.
This paper describes the preparation and characterization of
folic acid-conjugated liposomal vincristine (FA-PEG-LS/VCR)
and its anti-tumor efficacy on MDR tumor-bearing mice.2. Materials and methods
2.1. Materials
Folic acid-conjugated PEGylated distearoylphosphatidyl-
ethanolamine (FA-PEG3350-DSPE) was synthesized byourselves at lab [10]. Vincristine (VCR) was purchased from
Hanfang Pharmaceutical Co., Ltd., Guangzhou, China. MTT (3-
(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-pheny-tetrazoliumro-
mide) was purchased from Shisheng Cell Biological Co., Ltd.,
Shanghai, China. TUNEL kit was purchased from Roche Co.,
Ltd., Switzerland. DMEMmediumand FBS (fetal bovine serum)
were purchased from Gibco Co., Ltd., New York, USA. Hydro-
genated soybean phosphatidylcholine (HSPC) and methox-
ypolyethylene glycol-1,2- distearoylphosphatidylethanola-
mine (mPEG2000-DSPE) were purchased from Lipoid GmbH
(Ludwigshafen, Germany). Cholesterol was purchased from
Sinopharm Chemical Reagent Co., Ltd., China. Sephadex G50,
Sepharose CL-4B and 5-carboxy fluorescein (FAM) were pur-
chased from Sigma (St. Louis, USA). DiR (1,10-dioctadecyl-
3,3,30,30-tetramethyl indotricarbocyanine iodide) was from
Invitrogen, USA. Methanol, acetonitrile, and other HPLC grade
reagents were obtained from Fisher Scientific, USA. All
chemicals were analytic reagent grade.
Male nude mice of 4e6 weeks age were purchased from
Shanghai SLAC laboratory animal Co., Ltd., Shanghai, China
and kept under SPF conditions. All animal experiments were
carried out in accordance with guidelines evaluated and
approved by the ethics committee of Fudan University.
2.2. Preparation and characterization of liposomes
2.2.1. Preparation
Liposomes loaded with VCR, FAM or DiR were prepared
respectively for different uses by the thin-film hydration and
extrusion method. For VCR-loaded liposomes, a mixture of
HSPC/Cholesterol/mPEG2000-DSPE/FA-PEG3350-DSPE
(55:45:2:0 or 1, molar ratio) in CHCl3 was rotary evaporated to
form a thin film. The film was vacuum desiccated overnight
and hydrated using physiological saline or 0.155 M ammo-
nium sulfate solution (VCR-loaded liposomes) at 65 C water
bath for 2 h. The resulting solution was extruded through a
series of polycarbonatemembranes with the pore size ranging
from 200 nm down to 50 nm using an Avanti Mini Extruder
(Avanti Polar Lipids). An ammonium sulfate gradient method
was adopted to load VCR as previously described [11,12]. The
external water phase, ammonium sulfate solution, was
replaced by physiological saline solution through the
Sepharose CL-4B column. When the ratio of drug to lipid was
1:10 (weight ratio), the VCR sulfate solution and the above-
mentioned liposomewasmixed and heated for 15min at 65 C
in a water bath. Then, the liposomal VCR was separated from
free VCR on a Sepharose CL-4B column equilibrated with
normal saline. VCR concentrations in the liposomal samples
were calculated from absorption at 297 nm following disso-
lution in acidic isopropanol. The size of liposomes was
determined at 25 C by the dynamic light scattering method
(Nicomp 380ZLS Particle Sizer, PSS Corp., USA) and trans-
mission electron microscopy (TEM). For FAM-loaded lipo-
somes, they were prepared with similar procedure (the initial
FAM concentration for loading into liposomes is 1mg/ml). The
film was vacuum desiccated overnight, and hydrated using
FAM solution at 65 C water bath. The resulting solution was
extruded through a series of polycarbonate membranes as
mentioned before. The unloaded FAMwas also removed by gel
filtration over a Sephadex CL-4B column with physiological
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similar procedure except that DiR was dissolved in the CHCl3
solution in the beginning (the initial DiR concentration for
loading into liposomes is 0.1 mg/ml), and that the film was
hydrated using normal saline (NS). All the procedures were
conducted in darkness.
2.2.2. Characterization
2.2.2.1. Particle size and size distribution. The particle size and
size distribution of different liposomes were determined by
dynamic light scatteringmethod. The volume-weightedmean
value was obtained from triplicate samples.
2.2.2.2. Transmission electron microscopy observation. The
morphology and size of liposomes were observed using a
transmission electron microscope (TEM) (H-7000, Hitachi,
Japan). A drop of sample solution (2 mg/ml) was placed onto a
300-mesh copper grid coatedwith carbon. After 2min, the grid
was tapped with a filter paper to remove surface water, fol-
lowed by air drying and negatively stained with 2% phos-
photungstic acid for 30 s. The grid was dried at room
temperature and then observed by TEM.
2.2.2.3. Encapsulation efficiency (EE) and drug-loading effi-
ciency (DL). 2 ml liposome was divided into two equal parts,
named as sample A and B. A was demulsificated and vibrated
by acid isopropyl alcohol. B was filtered by CL-4B Sepharose
gel column and the free VCR-free liposomes were collected.
HPLC was adopted to determine the quality of VCR in A and B
[10]. A means the weight of feeding drug. B means the weight
of drug in liposomes. EE is calculated as following: EE
% ¼ (weight of the drug in liposomes)/(weight of the feeding
drug)  100%.
As to DL, the numerator in the formulawas the same as the
one of EE. The denominator is made of the feeding material
and drug. DL is calculated as following: DL% ¼ (weight of the
drug in liposomes)/(weight of the feeding material and
drug)  100%.
2.2.2.4. In vitro drug release test. In order to create pseudo-
sink conditions, the in vitro drug release from liposomes was
determined in phosphate buffer saline (PBS, 0.1 M, pH 7.4 and
5.0). 1 ml of drug-loaded liposome was filled into a dialysis
tube and the end sealed dialysis tube was immersed fully in
20 ml of the release medium in an erlenmeyer flask. The
erlenmeyer flasks were placed in an incubator at 37 C. At
predetermined time intervals, 20 ml of the releasemediumwas
with-drawn and replaced with an equal volume of fresh
release medium. The collected samples were analyzed by
HPLC under the same analytic conditions. The results of
triplicate measurements were used to calculate cumulative
drug release.
2.3. In vitro cell culture studies
2.3.1. Cell line and cell culture
KBv200 (multidrug resistant variant), a human nasopharyn-
geal epidermoid carcinoma cell line, induced by vincristine,
overexpressing P-gp and exhibiting drug-resistant phenotype
in vitro and in vivo when grown in nude mice was kindlydonated from Prof. Gengtao Liu, Institute of Materia, Peking
Union Medical College and Chinese Academy of Medical Sci-
ences (Beijing, China) [13]. The parental line, KB (human
nasopharyngeal epidermoid carcinoma cell) was obtained
from Shanghai Institute of Materia Medica, Chinese Academy
of Sciences. These two cell lines were grown using 75 cm3
flasks in a humidified 5% CO2/95% atmosphere incubator at
37 C, in DMEM medium, supplemented with 10% FBS and
100 U/ml penicillin and 100 mg/ml streptomycin. Cells grown
to confluence were subcultured every other day after trypsi-
nized with 0.25% trypsine-EDTA and diluted in fresh growth
medium.
2.3.2. Folate receptor binding activity of FA-PEG
KBv200 cells in logarithmic growth phase were digested by
trypsin-EDTA and then suspended by medium. These cells
were seeded in several 24-well plates. The plates were placed
in incubator (37 C, 5% CO2) overnight. On the second day, all
of the adherent cells were washed three times in medium
(Folic acid free) and cultured in the medium. On the third day,
the cells were washed in medium (Folic acid free) and divided
into three groups: (a) FA-PEG-FITC (synthetized by ourselves
[14]); (b) Folic acid þ FA-PEG-FITC; and (c) RGD-PEG-FITC
(synthetized by ourselves, too [14]). After incubation for 24 h
at 37 C, the media were removed and the cells were washed
by PBS (pH 7.4) for three times. At last, the cells were detected
by fluorescence microscope.
2.4. Targeting efficiency verification
2.4.1. In vitro evaluation
The KBv200 cells were incubated with FA-PEG-LS/FAM, PEG-
LS/FAM or free FAM in culturemediumwith 0.1% FBS for 2 h at
the concentration of 1 mM (FAM), washed with PBS (pH 7.4),
trypsinized and centrifuged at 1000 rpm for 5 min. The ob-
tained cell pellet was washed, resuspended in PBS and then
analyzed using a flow cytometer (FACS, BD, USA) for quanti-
tative analysis.
2.4.2. In vivo evaluation
To generate tumor xenograft, 1  107 KBv200 cells were
injected subcutaneously (s.c.) using a 26-gauge needle in the
left flank of the animals. The tumors reached palpable sizes of
10e20 mm3 at 14 days following tumor cell implantation. To
investigate the targeting ability of folate receptor-targeted li-
posomes to KBv200 MDR tumor, FA-PEG-LS/DiR were given by
tail vein injection, and PEG-LS/DiR was adopted as control
(0.1 ml per mouse, Concentration of DiR ¼ 0.2 mg/ml). At pre-
determined times post-injection, the mice were anesthetized
and detected in whole body using an in vivo imaging system
(FX Pro, Kodak, Rochester, NY, USA) equipped with IR820 filter
sets (excitation/emission, 730/790 nm). Fluorescence images
and X-ray images were fused together with Kodak Molecular
Imaging Systems software v5.0.1.
2.5. Cytotoxicity assay
2.5.1. Pharmacodynamics in vitro
The in vitro anti-tumor activity of drug-loaded liposomes
and free drugs were determined by MTT assay. KBv200 and
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5000 cells/well/200 ml medium. Following attachment over-
night, the culture medium in each well was replaced with
200 ml of medium containing serial dilutions of treatment
drugs. The treatments included FA-PEG-LS/VCR, PEG-LS/
VCR, free VCR and control group. Cells were incubated with
treatments for 2 h, and the cells were subsequently washed
and incubated in media for a total of 72 h before assessing
cell viability. 200 ml of 5 mg/ml MTT dissolved in PBS was
added to each well. The plates were incubated for an addi-
tional 4 h at 37 C and then the medium was discarded.
Thereafter, 200 ml of DMSO was added to each well to
dissolve the formazan crystals while vigorously stirring the
plates using an automated shaker. The absorbance of each
well was read on a microplate reader (Bio-Rad 680, USA) at a
test wavelength of 570 nm and reference wavelength
630 nm.
In this assay, all the experiments were done with 6 par-
allel samples. Untreated cells, blank liposomal solution and
culture medium containing 0.1% DMSO were also tested as
controls. Results were presented as cell inhibitory rate and
IC50 values. The percentage of cell growth inhibition was
calculated as follows: inhibitory rate ¼ (A570control
A570sample)/A570control  100%. The cytotoxicity of drug-loaded
liposomes was expressed as IC50 values, defined as the drug
concentration required to inhibit growth by 50% relative to
controls, which were calculated using nonlinear regression
analysis.
2.5.2. Mechanism of MDR
VRP was used as a useful tool to verify whether the MDR
effect raised by KBv200 cell was attributed to p-gp. Cells
were cultured as described in 2.5.3 and were divided into
two groups: Group 1 and Group 2. Group 1 were given the
following serial diluted drug treatments: (a) FA-PEG-LS/
VCR (0.025 nM-25 mM in VCR); (b) PEG-LS/VCR (0.06 nM-
60 mM in VCR); and (c) free VCR (2.5 nMe2.5 mM in VCR).
Group 2 was given a certain concentration VRP solution
(5 mM) prior to the above-mentioned three serial
dilutions.
The follow-up operation was the same as 2.5.1.
2.6. Antitumor efficacy study
2.6.1. Tumor growth inhibition
On day 0 (14 days after tumor cell implantation) when the
tumors reached sizes of 10e20 mm3, the mice were
divided into groups (eight each) received one of the
following treatments: high dosage FA-conjugated lipo-
somal VCR (6 mg/kg, FA-PEG-LS/VCR, Group I), low dosage
FA-conjugated liposomal VCR (2 mg/kg, FA-PEG-LS/VCR,
Group II), liposomal VCR (2 mg/kg, PEG-LS/VCR, Group
III), free VCR (2 mg/kg, Group IV) and physiological
saline (Group V). The drug was given by tail vein injection
on every four days for three doses. Tumor size was
measured on every second day, and animal survival
was monitored daily. Tumor size was calculated using the
equation: volume ¼ maximal diameter  (minimum
diameter)2  0.5. The mice weight was recorded on every
2nd day.2.6.2. Apoptosis assessment
MDR tumor cell apoptosis was assessed by TUNEL using
ApopTag alkaline phosphatase in situ Apoptosis Detection
kit. Following TUNEL staining, sections were counter-
stained with Harris Hematoxylin and mounted under
glass cover slips. The sections were examined and scored
under a light microscope (Nikon; YS100) equipped with a
digital camera. Apoptotic index was the ratio of TUNEL-
positive cells to negative ones and for this purpose sec-
tions in at least 5 random fields per tumor were analyzed.
As negative controls, a section from each animal was
processed, but terminal transferase was omitted from the
Terminal deoxynucleotidyl transferase (TdT) labeling
buffer and for positive controls DNAse was added on the
sections [15].
2.7. Statistical analysis
All represented data are expressed as mean  SD, with stan-
dard error shown afterward in parentheses. Statistical differ-
ences were evaluated by using the FT-test or ANOVA. Results
were considered statistical significant at the 95% confidence
interval (i.e., p < 0.05). The IC50 values were calculated by
nonlinear regression analysis with the GraphPad Prism 5.0
version program. All figures shown in this article were ob-
tained from at least three independent experiments.3. Results and discussion
3.1. Characterization of liposomes
3.1.1. Vesicle size, encapsulation efficiency and drug-loading
efficiency
The average vesicle size of FA-PEG-LS/VCR, PEG-LS/VCR, FA-
PEG-LS/FAM, PEG-LS/FAM, FA-PEG-LS/DiR, PEG-LS/DiR was
79.79 4.43 nm (n¼ 18). The polydispersity index of the above-
mentioned formulations is 0.023  0.008 (n ¼ 18). The lipo-
somes with or without folic acid modification showed similar
vesicle size and polydispersity index, indicating that the
incorporation of FA-PEG-DSPE into liposomes had no influ-
ence on the physical properties of liposomes. The nano-
particle size was confirmed by TEM (Fig. 1). The EE and DL of
VCR in liposomes are 91.11  1.58% (n ¼ 3) and 5.23  0.09%
(n ¼ 3) respectively.
3.1.2. Release characteristics
The rate and extent of VCR release from FA-PEG-LS/VCR in the
pH 5.0 PBS buffer are both higher than the ones in the pH 7.4
PBS buffer. The 72 h cumulative release in pH 7.4 media is
more than 90%, whereas that in pH 5.0 media is about 80%,
which indicates that the low pHhelps to accelerate the release
of VCR from liposomes (Fig. 2).
The pH decreases continuously during the internalizing
process of liposome through endosome. The pH value of the
early endosome is reported to be about 6.5. Meanwhile, the pH
of late endosome commonly varies between 5.0 and 6.0. The
destination of the folate receptor-mediated endocytosis is
lysosome, where the pH value varies between 4.0 and 5.0 [16].
Therefore, with the deepening of the internalization, the
Fig. 1 e TEM images of PEG-LS (A), FA-PEG-LS (B), PEG-LS/VCR (C) and FA-PEG-LS/VCR (D).
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becoming lower and lower, which will accelerate the release
rate of VCR from liposomes. It was also confirmed that the pH
value of normal tissue varied between 7.2 and 7.6. Production
of lactic acid and hydrolysis of ATP are the major contributors
to the acidic environment around the tumor, where the pH
value is a little lower than normal tissues, ranging from 6.8 to
7.2, which is still much higher than the pH of the endosomes
and lysosomes [17,18]. Thus it can be seen that FA-PEG-LS/Fig. 2 e Release profile of FA-PEG-LS/VCR at different pH.VCR drug delivery system helps to the drug release in the
targeted cells.
3.2. Targeting ability
3.2.1. FR binding activity of FA-PEG
As showed in Fig. 3, the left column indicated that in the folic
acid-deficient medium FA-PEG labeled with FITC (FA-PEG-
FITC) was taken up by KBv200 cells, meanwhile, the middle
column indicated that the free folic acid blocked the KBv200
cells from uptaking FA-PEG-FITC. The right column indicated
that no significant RGD-PGE-FITC was detected in the cells.
The results confirmed that: 1. the ability of FA-conjugate PEG
to bind FR on the surface of the tumor cell line is strong; 2. FA-
PEG-FITC entered into KB cells through the FR endocytosis
pathway; 3. there were few RDG receptors on the surface of
KBv200 cells. Therefore, folic acid is more potent to enhance
the targeting efficiency than RDG, another widely used tar-
geting molecule.
3.2.2. Targeting ability in vitro
After KBv200 cells were incubated with FA-PEG-LS/FAM,
PEG-LS/FAM and free FAM for 1 h at 37 C, the flow cytom-
etry assay results indicated that this kind of cell took up FA-
PEG-LS/FAM for the most among these three formulations,
up to 90.7% positive cells. The cells also took up some PEG-
LS/FAM, rendering 30.6% cells FAM positive. However, as to
Fig. 3 e Cellular accumulation of fluorescein-labeled PEG conjugates in KBv200 cells. Cells were incubated with 0.5 mM
substrates for 24 h at 37 C and photographed in both the phase-contrast and fluorescence mode on microscope as
described inmethods. Lower panels, micrographs taken in the phase-contrast mode; upper panels, the same field viewed in
the fluorescence mode.
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positive proportion (Fig. 4). These results indicate that FA
modification helps to strengthen the affinity between lipo-
somes and cells.
3.2.3. Targeting ability in vivo
The results of in vivo uptake of FA-PEG-LS by MDR tumors
showed that significantly more FA-PEG-LS/DiR were captured
by MDR tumors than PEG-LS/DiR were. The semi-quantitative
analysis of the region of interest (ROI) revealed that there was
a 67.53% increase in the area under curve (AUC) of DiR in MDR
tumors due to FA mediation (AUCFA-PEG-LS/DiR ¼ 16,792;
AUCPEG-LS/DiR ¼ 10,023) (Fig. 5).
3.2.4. Discussion
Folic acid has great virtues as a targeting moiety of
nanoparticulate drug delivery system: 1) Its receptor, folateFig. 4 e In vitro binding ability to tumor cells. Cellular uptake o
KBv200 cells was examined by flow cytometry. Numbers shown
intensity, respectively.receptor is upregulated in many human cancers, including
tumors of the ovary, breast, brain, kidney and lung [19],
with expression rate correlated with higher histological
grade, more advanced stage and stronger resistance to
chemotherapeutics [20]. 2) Folate receptors are selectively
expressed on the apical membrane of polarized epithelial
cells, which are inaccessible to intravenous drugs, while
turn accessible after malignant transformation with po-
larity lost [11]. Therefore, folate receptor-mediated drug
delivery systems are expected to target tumor cells, with
slight adverse effects on normal cells. 3) Folic acid has a
high binding affinity (Kd: w10
10), low immunogenicity,
ease of modification, small size (MW: 441.4 g/mol), stability
during storage, compatibility with a variety of organic and
aqueous solvents, low cost, and ready availability, making
it a very popular molecule for targeting malignant cells
[21].f FA-PEG-LS/FAM (A), PEG-LS/FAM (B) and free FAM (C) by
in inset mean% FAM-positive cells and mean fluorescence
Fig. 6 e Concentration-dependent cell viability curve of
various VCR formulations against KBv200 in vitro by MTT
assay (n [ 6).
Fig. 5 e Pharmacokinetic profiles of DiR in MDR tumors of KBv200 tumor-bearing nude mice models of FA-PEG-LS/DiR and
PEG-LS/DiR based on the semi-quantitative ROI analysis of in vivo fluorescent images. Near-infrared in vivo fluorescence
imaging showed a qualitative result.
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3.3.1. Pharmacodynamics in vitro
3.3.1.1. Cytotoxicity. The cytotoxicities of various VCR for-
mulations were compared on KBv200 cells. VCR concentra-
tions leading to 50% cell-killing (IC50) were determined from
concentration-dependent cell viability curves. As shown in
Fig. 6, the IC50 of FA-PEG-LS/VCR was 23.99 nM, which was
approximately 46 and 15 folds lower than that of free VCR
(1.10 mM) and PEG-LS/VCR (363.08 nM), respectively.
3.3.1.2. Verification of the MDR mechanism. In most of the
MDR cells which are induced by VCR, the expression level of
mdr-1 gene, which encodes P-gp, will rise steeply after the
stimulation of VCR, resulting in the increase of the intracel-
lular P-gp concentration. VCR, doxorubicin, paclitaxel and
some other cytotoxic agents are all the substrates of P-gp,
which will lead to the acquirement of MDR [22,23].
KBv200 cells were incubated with the various formulations
of VCR (FA-PEG-LS/VCR, PEG-LS/VCR, and free VCR) with or
without VRP pretreatment. (The VRP concentration is 5 mM).
The results indicated that the IC50 curves shifted left signifi-
cantly after the inhibition of VRP. It meant that KBv200 cells
had become more sensitive to VCR (no matter what formula-
tion it was) after VRP pretreatment. However, the VCR sensi-
tivity of KB cells didn’t show any significant difference by VRP
pretreatment, which indicated that VRP didn’t impact greatly
on KB cells (Fig. 7). It can be concluded that P-gp plays a vital
role in the MDR mechanism observed in KBv200 cells.
As shown in Table 1, the cytotoxicity of FA-PEG-LS/VCR,
PEG-LS/VCR, free VCR was about 3.11, 3.23, 5.50-fold
increased by VRP pretreatment, respectively. The cytotox-
icity increase was the highest in the case of free VCR while
that was the least from FA-PEG-LS/VCR. It seems likely thatthe cytotoxic strength of free VCRwas greatly induced by VRP-
mediated P-gp inhibition. However, because the cytotoxicity
of VCR encapsulated in FA-PEG-LS was already greatly
enhanced by being encapsulated in liposomes and modified
by folic acid, the VRP inhibition effect was negligible.
P-gp is a kind of ATP-dependent MDR protein. When a
substrate is pumped out of a cell by P-gp, it will cost an ATP
[24]. It will also cost ATPs when liposomes are endocytosed by
cells. Therefore, the ATPs cost by the endocytosis of liposomal
VCR aremuchmore than the one cost by diffusion of free VCR.
Generally speaking, it is difficult for the water-soluble
vincristine sulfate to penetrate the cellular phospholipid
bilayer by diffusion. The ATP pool volume is a constant value.
If it distributes more energy to the endocytosis process, it will
Table 1 e IC50 value of three various kinds of VCR
formulation with/without VRP inhibition on KBv200 and
KB cells.
Formulations IC50 (nM)
KBv200 KB
FA-PEG-LS/VCR 26.92 0.15
VRP þ FA-PEG-LS/VCR 8.66 0.12
PEG-LS/VCR 398.11 2.56
VRP þ PEG-LS/VCR 123.03 2.55
Free VCR 1584.89 5.11
VRP þ Free VCR 288.40 3.52
Fig. 7 e Growth inhibition curves of KBv200 and KB cells. Cells were treated with FA-PEG-LS/VCR, PEG-LS/VCR and free VCR
with/without VRP from left column, through middle one, to right one, respectively. Upper and lower panel represented
KBv200 and KB cells respectively.
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P-gp. Consequently, P-gp will play a less important role in the
MDR mechanism. Therefore, the synergistic effect achieved
by VRP inhibition and liposomal VCR drug delivery is not as
significant as the one achieved by VRP inhibition and free VCR.
3.3.2. Pharmacodynamics in vivo
3.3.2.1. Tumor growth inhibition efficacy. By a preliminary
test, we set 2 mg/kg as the administration dosage because of
its anti-tumor efficacy. Five different treatment groups: high
dosage Folic acid-conjugated liposomal VCR (6mg/kg, FA-PEG-
LS/VCR, Group I), low dosage Folic acid-conjugated liposomal
VCR (2mg/kg, FA-PEG-LS/VCR, Group II), liposomal VCR (2mg/
kg, PEG-LS/VCR, Group III), free VCR (2 mg/kg, Group IV) and
physiological saline (Group V). The tumor volume is a reliable
indicator to evaluate the anti-tumor efficacy of the drug de-
livery system on the solid tumor models. As showed in Fig. 8,
the tumor inhibition rate for group I, II, III, IV is 74.75%, 60.11%,
44.25%, 42.60% (in volume), respectively and 69.55%, 59.98%,
44.01%, 39.27% (in weight) respectively.
Results indicated that: 1. Falic acid modification signifi-
cantly strengthened the anti-tumor efficacy of the PEGylated
liposomal VCR; 2. PEGylation significantly strengthened the
anti-tumor efficacy of the cytotoxic agents; 3. Falic acid-
conjugated PEGylated liposomal VCR showed dosage-
dependent characteristics.
3.3.2.2. Apoptosis-inducing ability. Recently, apoptosis assay
has been adopted to evaluate the efficacy of chemotherapy. It
has been a new demand for doctors to raise the ratio between
the apoptotic cell numbers and proliferating cell numbers. In
addition, apoptosis play a negative role in regulating the
tumorigenesis process, which can inhibit the growth oftumors, weaken the infiltrating and transferring ability of tu-
mors. Therefore, apoptotic detection is a fast and effective
method to screen anti-tumor agent. TUNEL assay is used to
demonstrate the proportion of apoptotic cells in a tumor tis-
sue section whose nuclei are brown yellow or brown sepia.
Apoptotic index (AI) refers to the percentage of positive cells in
a high power field.
AI of FA-PEG-LS/VCR group showed significant difference
with PEG-LS/VCR, free VCR and physiological saline group
(P < 0.01). The AI value of these four groups were
24.1  3.1%, 14.4  3.2%, 11.8  4.4%, 5.6  2.2% respectively
(n ¼ 3, Fig. 9).
3.3.3. Discussion
Although a large number of experimental data in this field
indicated folic acid is an ideal ligand of liposomes for targeted
delivery to tumors, the related clinical trials are few. There are
some in vivo limitations of folic acid as a targeting moiety:
Fig. 8 e Tumor growth inhibition by multiple injections of various VCR formulations in tumor-bearing mice. Mice with
KBv200 tumor xenografts were treated with multiple injections (given on every 4 days, as indicated by the arrows) of
various VCR formulations. Tumor size was measured for each animal every 2 days starting from the day of the initial
treatment (n [ 6).
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somes is that liposomes are bulky structures that have diffi-
culty penetrating solid tumors. This may reduce their ability
to reach a significant number of target cells located away for
the vessel lining [25].Fig. 9 e Tumor tissue sections of TUNEL assay. Significant differe
III, IV and V were showed respectively (**P< 0.01, vs FA-PEG-LS
1-HE, 2-TUNEL).Another potential disadvantage of liposomes is that
intracellular delivery of nanoparticles, including folic acid-
conjugated liposomes, as opposed to water-soluble polymer-
drug conjugates, often leads to sequestration of the drug in
lysosomes, rather than delivery to the cytosol. If drug escapence analysis of AI by histogram. From left to right, Group II,
/VCR; A e Group II, B e Group III, C e Group IV, D e Group V;
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 1 1 8e1 2 7 127from the lysosome is compromised, this may reduce its effi-
cacy [26].
There must be other factors accounting for the application
of folic acid as a targetingmoiety.We think it really need great
efforts to clear whether and how folic acid-targeted nano-
medicines can provide a significant added value in clinical
applications.4. Conclusion
FA-PEG-LS/VCR, a new liposomal drug delivery system (DDS)
for MDR cancer therapy, was constructed successfully. It
showed significant advantages that targeting ability and
inhibiting tumor growth in vitro and in vivo. The DDS proves to
a wide potential clinical application.
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